



## Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings

April 29, 2021

MARLBOROUGH, Mass., April 29, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced new data to be presented at the upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), which is being held on May 11 - May 14, 2021, and the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held on June 4 - 8, 2021.

Logo - [https://mma.prnewswire.com/media/786567/Phio\\_Pharmaceuticals\\_Logo.jpg](https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg)

### Details are as follows:

Event: 24th Annual Meeting of the ASGCT  
INTASYL PH-762 Self-Delivering RNAi Targeting PD-1 Enhances the Therapeutic Efficacy of Systemically Administered

Poster Title: HER2-Targeted CAR-T Cells in a SKOV3 Model of Human Ovarian Adenocarcinoma in NCG Mice

Authors: Benjamin Cuiffo, et al.

Abstract Number: 431

Date/Time: 8:00 AM - 10:00 AM on Tuesday, May 11, 2021

  

Event: The 2021 ASCO Annual Meeting  
INTASYL Self-Delivering RNAi Therapy Specifically Dual-Targeting BRD4 and PD-1 Elicits Complete Tumor Responses and

Poster Title: Evidence of Synergy in a Subcutaneous Hepa1-6 Model of Murine Hepatoma in C57BL/6N Mice

Authors: Benjamin Cuiffo, et al.

Abstract Number: e14537

Date: Friday, June 4, 2021

Archived versions of the Phio presentations will be made available on the "Investors – Events and Presentations" section of the Company's website ([click here](#)).

### **About Phio Pharmaceuticals Corp.**

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, [www.phio-pharma.com](http://www.phio-pharma.com).

### **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the impact to our business and operations by the recent coronavirus outbreak, results from our preclinical and clinical activities, the development of our product candidates, the ability to obtain future financing, the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

### **Contact Phio Pharmaceuticals Corp.**

[ir@phio-pharma.com](mailto:ir@phio-pharma.com)

### **Investor Contact**

Ashley R. Robinson

LifeSci Advisors

[arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)

 View original content: <http://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-upcoming-data-presentations-at-the-asgct-and-asco-annual-meetings-301279761.html>

